Physician Assistant Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Kali Schirra

Physician Assistant Sugarloaf, PA Physician Assistant

NPI 1871218198 CMS profile 11408175

8 Brookhill Sq S, Sugarloaf, PA 18249

Open in the dashboard

General payments

$10,587

616 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kali Schirra of Sugarloaf, PA is reported in the CMS Open Payments database as having received $10,587 across 616 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,568 143
2024 General $3,578 221
2023 General $3,994 234
2022 General $448 18

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kali Schirra
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Kali Schirra were reported at $2,568. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Kali Schirra Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $0 $132 $37–$438 $132
2022 $448 $155 $48–$522 $149
2023 $3,994 $167 $52–$557 $160
2024 $3,578 $178 $55–$600 $164
2025 $2,568 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Janssen Biotech, Inc. $1,968 94 payments
  2. AbbVie, Inc. $1,802 138 payments
  3. UCB, Inc. $988 82 payments
  4. Regeneron Healthcare Solutions, Inc. $845 23 payments
  5. Sun Pharmaceutical Industries Inc. $734 28 payments
  6. Lilly USA, LLC $662 31 payments
  7. Novartis Pharmaceuticals Corporation $625 48 payments
  8. Dermavant Sciences, Inc. $536 33 payments
  9. LEO Pharma Inc. $520 44 payments
  10. Genzyme Corporation $470 21 payments
  11. Other $1,436 74 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $10,159 610 payments
  2. Education $428 6 payments
Products named General payments · program years 2022–2025
  1. TREMFYA $2,015 95 payments
  2. RINVOQ $806 41 payments
  3. DUPIXENT Inflammation And Immunology $775 21 payments
  4. DUPIXENT Immunology $746 33 payments
  5. SKYRIZI $697 67 payments
  6. ILUMYA $656 24 payments
  7. Bimzelx $580 44 payments
  8. VTAMA $536 33 payments
  9. TALTZ $525 25 payments
  10. ADBRY $463 42 payments
  11. Other $3,432 228 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 18 drugs

Part D claims

587

Median for Physician Assistant: 241

Drug cost

$15,239

Median for Physician Assistant: $4,110

Branded share of claims

0%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Clobetasol Propionate Generic 78 $3,387
Acitretin Generic 12 $2,288
Ketoconazole Generic 98 $1,606
Clindamycin Phosphate Generic 51 $1,365
Triamcinolone Acetonide Generic 70 $1,096
Doxycycline Monohydrate Generic 30 $961
Betamethasone Dipropionate Generic 21 $887
Mometasone Furoate Generic 48 $839
Hydrocortisone Generic 44 $581
Tretinoin Generic 11 $577

The 10 drugs with the highest cost, of 18 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 29 billing codes

Paid by Medicare

$51,150

Of which drugs: $49

Medicare patients

431

Average age 74

Services billed

1,480

246 women, 185 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 56%
Diabetes 30%
Ischemic heart disease 26%
Chronic kidney disease 22%
COPD 16%
Osteoporosis 16%
Depression 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 22 79 $49

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 25 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TREMFYA
  • Janssen Biotech, Inc. $544
$544 — —
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $382
  • GENZYME CORPORATION $131
$514 — —
Bimzelx
  • UCB, Inc. $323
$323 — —
SKYRIZI
  • AbbVie, Inc. $299
$299 — —
ADBRY
  • LEO Pharma Inc. $283
$283 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 25 in the dashboard with a free account

Records

616 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record